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Rapidly Progressive Dementia:  
Is it Alzheimer’s or Not?
Anna Maria Mouzak, MD
A b s t r A c t
Alzheimer’s disease is a chronic progressive disease, which accounts for 60% of all 
dementias. Sometimes 10-30% of Alzheimer’s disease cases have a more fulminant 
course, but this subtype is not the only cause of rapidly progressive dementia. There 
exists a variety of entities presenting as rapidly progressive dementias, a number of 
which are reversible or treatable. It is imperative that accurate and prompt diagno-
sis be made, since it is crucial for neuronal survival. Some of these rapidly progres-
sive manifestations concern vascular, infectious, toxic-metabolic, autoimmune, met-
astatic-neoplastic, iatrogenic, neurodegenerative or systemic diseases, which can be 
arranged in a list using the mnemonic “VITAMINS”. This review summarizes the 
major aetiologies of rapidly progressive dementia. Differential diagnostic algorithms 
are also presented.
I n t r o d u c t I o n
Dementia, a clinical syndrome which encompasses a variety of diseases, is charac-
terized by a cluster of symptoms and signs manifesting as loss of executive functioning, 
concerning the ability of decision making, cognitive decline, memory impairment, 
language disturbances, psychiatric and psychological changes leading to impaired per-
formance in daily living activities. Usually of a gradually progressive course, dementia 
is considered one of the major causes of disability and dependency. Its prevalence is 
rising rapidly, especially after the seventh decade of life. The total number of people 
in 2010 was estimated to be about 35.6 million and is expected to reach 115.4 million 
by 2050.1-3 
Alzheimer’s disease (AD) is considered the most common type of dementia, fol-
lowed by vascular dementia (VD). The combination of AD and VD (mixed dementia) 
has been considered by some studies as not only a subtype of dementia, but also the 
most frequent. There seems to be a gender difference in the prevalence of dementia 
subtypes. Women in the older age group (85 years and more) are more likely to develop 
AD, while men vascular dementia, atherosclerotic cardiovascular diseases or stroke. In 
2011 the National Institute on Aging- Alzheimer’s Association (NIA-AA), led by the 
vast evolution of neuroimaging and biomarkers, presented new criteria for all cause 
dementia and AD, definite diagnosis being made only post-mortem (Tables 1a, b, c, 
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Table 1a. Criteria for all-cause dementia as quoted 
from and according to the 2011 recommendations of the 
NINCDS-ADRDA4,5 
Dementia is diagnosed when there are cognitive or 
behavioral (neuropsychiatric) symptoms that: 
1. Interfere with the ability to function at work or at usual 
activities; 
2. Represent a decline from previous levels of functioning 
and performing; and
3. Are not explained by delirium or major psychiatric 
disorder;
4. Cognitive impairment is detected and diagnosed through 
a combination of (1) history-taking from the patient and a 
knowledgeable informant and (2) an objective cognitive 
assessment, either a “bedside” mental status examination 
or neuropsychological testing. Neuropsychological testing 
should be performed when the routine history and bedside 
mental status examination cannot provide a confident 
diagnosis.
5. The cognitive or behavioral impairment involves a 
minimum of two of the following domains:
a) Impaired ability to acquire and remember new 
information—symptoms include: repetitive questions 
or conversations, misplacing personal belongings, 
forgetting events or appointments, getting lost on a 
familiar route.
b) Impaired reasoning and handling of complex 
tasks, poor judgment—symptoms include: poor 
understanding of safety risks, inability to manage 
finances, poor decision-making ability, inability to plan 
complex or sequential activities.
c) Impaired visuospatial abilities—symptoms include: 
inability to recognize faces or common objects or 
to find objects in direct view despite good acuity, 
inability to operate simple implements, or orient 
clothing to the body.
d) Impaired language functions (speaking, reading, 
writing)—symptoms include: difficulty thinking of 
common words while speaking, hesitations; speech, 
spelling, and writing errors.
e) Changes in personality, behavior, or comportment
Table 1b. Criteria for Alzheimer’s Disease as quoted 
from and according to the 2011 recommendations of the 
NINCDS-ADRDA.4,5
aD is classified in: (1) Probable aD dementia, (2) Possible 
aD dementia, and (3) Probable or possible aD dementia 
with evidence of the aD pathophysiological process
1.  Probable AD Dementia: Meets criteria for dementia 
described in section I, and in addition, has the following 
characteristics: 
A.  Insidious onset. Symptoms have a gradual onset over 
months to years, not sudden over hours or days; 
B.  Clear-cut history of worsening of cognition by report 
or observation; and 
C.  The initial and most prominent cognitive deficits 
are evident on history and examination in one of the 
following categories.
a) Amnestic presentation: It is the most common 
syndromic presentation of AD dementia. The deficits 
should include impairment in learning and recall 
of recently learned information. There should also 
be evidence of cognitive dysfunction in at least one 
other cognitive domain, as defined earlier in the text.
b) Nonamnestic presentations: Language presentation: 
The most prominent deficits are in word-finding, but 
deficits in other cognitive domains should be present. 
Visuospatial presentation: The most prominent 
deficits are in spatial cognition, including object 
agnosia, impaired face recognition, simultanagnosia, 
and alexia. Deficits in other cognitive domains 
should be present. Executive dysfunction: The most 
prominent deficits are impaired reasoning, judgment, 
and problem solving. Deficits in other cognitive 
domains should be present.
D.  The diagnosis of probable AD dementia should not be 
applied when there is evidence of (a) substantial 
concomitant cerebrovascular disease, defined by a 
history of a stroke temporally related to the onset or 
worsening of cognitive impairment; or the presence of 
multiple or extensive infarcts or severe white matter 
hyperintensity burden; or (b) core features of Dementia 
with Lewy bodies other than dementia itself; or (c) 
prominent features of behavioral variant frontotemporal 
dementia; or (d) prominent features of semantic variant 
primary progressive aphasia or nonfluent/agrammatic 
variant primary progressive aphasia; or (e) evidence 
for another concurrent, active neurological disease, 
or a non-neurological medical comorbidity or use 
of medication that could have a substantial effect on 
cognition.
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Table 1c. Criteria for Possible and Pathophysiologically 
proven AD dementia as quoted from and according to the 
2011 recommendations of the NINCDS-ADRDA.4,5
2. A. Possible AD dementia
•  Atypical course meets the core clinical criteria in 
terms of the nature of the cognitive deficits for AD 
dementia, but either has a sudden onset of cognitive 
impairment or demonstrates insufficient historical 
detail or objective cognitive documentation of 
progressive decline.
•  Etiologically mixed presentation meets all core 
clinical criteria for AD dementia but has evidence of 
(a) concomitant cerebrovascular disease, defined by 
a history of stroke temporally related to the onset or 
worsening of cognitive impairment; or the presence of 
multiple or extensive infarcts or severe white matter 
hyperintensity burden; or (b) features of Dementia 
with Lewy bodies other than the dementia itself; or (c) 
evidence for another neurological disease or a non-
neurological medical comorbidity or medication use 
that could have a substantial effect on cognition.
B. Pathophysiologically proven AD dementia
The diagnosis of pathophysiologically proved  
AD dementia would apply if the patient meets  
the clinical and cognitive criteria for AD dementia 
outlined above, and the neuropathological  
examination demonstrates the presence of  
the AD pathology.
Dementia unlikely to be due to AD
1. Does not meet clinical criteria for AD dementia.
2. a.  Regardless of meeting clinical criteria for probable 
or possible AD dementia, there is sufficient 
evidence for an alternative diagnosis such as HIV 
dementia, dementia of Huntington’s disease, or 
others that rarely, if ever, overlap with AD.
b.  Regardless of meeting clinical criteria for possible AD 
dementia, both Aβ and neuronal injury biomarkers 
are negative
Table 1D. Criteria for Probable and Possible AD dementia 
with evidence of the AD pathophysiological process as 
quoted from and according to the 2011 recommendations 
of the NINCDS-ADRDA.4,5
•  Probable AD dementia with evidence of the AD 
pathophysiological process 
Major AD biomarkers that have been widely investigated 
and may be broken into two classes based on the biology 
which they measure. Biomarkers of brain amyloid-beta 
(Aβ) protein deposition are low CSF Aβ42 and positive 
PET amyloid imaging. The second category is that of 
biomarkers of downstream neuronal degeneration or 
injury. The three major bio-markers in this category are 
elevated CSF tau, both total tau and phosphorylated tau 
(p-tau); decreased 18fluorodeoxyglucose (FDG) uptake 
on PET in temporo–parietal cortex; and disproportionate 
atrophy on structural magnetic resonance imaging in me-
dial, basal, and lateral temporal lobe, and medial parietal 
cortex. 
In persons who meet the core clinical Criteria 
for probable AD dementia biomarker evidence 
may increase the certainty that the basis of the clinical 
dementia syndrome is the AD pathophysiological 
process. However, we do not advocate the use of AD 
biomarker tests for routine diagnostic purposes at 
the present time. Biomarker test results can fall into 
three categories–clearly positive, clearly negative, and 
indeterminate.
•  Possible AD dementia with evidence of the AD 
pathophysiological process 
This category is for persons who meet clinical criteria 
for a non-AD dementia but who have either biomarker 
evidence of AD pathophysiological process, or meet 
the neuropathological criteria for AD. Examples would 
include persons who meet clinical criteria for dementia 
with Lewy bodies or for a subtype of frontotemporal lobar 
degeneration, but who have a positive AD biomarker 
study or at autopsy are found to meet pathological criteria 
for AD. In the biomarker table, we indicate that both 
categories of biomarkers must be positive for an individual 
who presents clinically with a non-AD phenotype to meet 
criteria for possible AD. 
d).4,5 AD demonstrates a clinical heterogeneity. Different sub-
types have been verified, such as late and early-onset, familial, 
sporadic and rapidly progressive (rpAD).6,7 In the following 
review the rapidly progressive subtype of AD is discussed and 
differential diagnosis from other similar entities presented.
r A p I d l y  p r o g r e s s I v e  A l z h e I m e r ’ s 
d I s e A s e
Classical AD’s duration ordinarily varies from a few years 
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to two decades with a mean 8 year survival rate. There is about 
a 3 Mini- Mental State Examination (MMSE) point decline 
in cognition per year. Attempts have been made to define 
the diverse types of AD by specifying the cognitive disorder 
features (frontal, cortical, subcortical), the cerebrospinal fluid 
(CSF) biomarker profiles, genetic testing and neuroimaging 
findings for each one. Despite the multiversity of AD and the 
different biological aetiologies of its subgroups, in the end 
there is a similar evolution. This is characterized by accumu-
lation of β-amyloid (Aβ) plaques and neurofibrillary tangles, 
composed of tau fibrils, with subsequent synapse and neuronal 
loss. Amyloid precursor protein (APP), which is a membrane 
bound protein, normally undergoes endoproteolytic cleavage 
by enzyme α- secretase forming soluble fragments. When there 
is abnormal APP cleavage by β- and γ-secretases, accumulation 
of Aβ peptide is observed, thus launching the pathogenic self-
sustaining cascade. Other proteins such as presenelin 1 and 2 
also participate in Aβ protein production.6-8
Concerning the more rapidly evolving type of AD, it has 
been the object of dispute mainly regarding the term “rapid”. 
The term rapid has been used to describe not only cognitive 
decline, evaluated by MMSE or Clinical Dementia Rating 
Scale (CDR), but survival rate as well. Reaching a consensus 
rapidly progressive Alzheimer’s disease (rpAD) has been 
defined as a six –point decline in cognitive performance as 
evaluated by MMSE or survival rate of less than two years. 
RpAD patients represent 10-30% of AD cases according to 
the different definitions given.6,8
The factors contributing to the rapid progression of AD 
continue to be under investigation. Rapid cognitive deteriora-
tion has been related to high ratio of total tau to β- amyloid 
1-42 (Aβ1-42 ) protein (≥81), high levels of total tau protein 
or phosporylated tau (ptau) and low Aβ1-42 (≤411pg/mL) 
in the CSF. CSF protein 14-3-3, usually detected in patients 
with Creutzfeldt-Jakob disese, is sometimes detected in fast 
evolving AD cases.9
Genetic factors have also been associated with rpAD, 
though occasionally controversial, as in the case of the presence 
or not of the Apolipoprotein E εallele or the polymorphisms 
of the G51S purine nucleoside phorylase, presenelin/rs3025780 
(T6 genotype) and others.10-14
Comorbidities also seem to play an important role in the 
progression of AD. Among these are the pre-existing cognitive 
reserve, diabetes mellitus, atherosclerosis, hypertension, atrial 
fibrillation, hypercholesterolemia, myocardial infarction and 
others.15,16 Proof for the above is the fact that hyperglycemic 
conditions and impaired glucose metabolism in general have 
been known to provoke accumulation of a-ketoaldehyde 
methylglyoxal (MG). MG, a reactive intermediate of cellular 
metabolism, has been correlated with oxidative stress in AD. 
It is formed endogenously as a by-product of the glycolytic 
pathways and is able to induce cellular damage by linking 
proteins and glycation. MG furthermore induces tau hyper-
phosporylation by reducing phosphatise levels and enhancing 
kinase activities.17
Another crucial issue arising is the differential diagnosis 
of rpAD. Are all rpAD patients with a condemned at present 
diagnosis?
r A p I d l y  p r o g r e s s I v e  d e m e n t I A s
A considerable number of nosologies other than rpAD 
have a rapid cognitive deterioration of which a numerous 
amount are reversible and some are not. It is imperative in the 
event of treatable causes to make a swift and accurate diagnosis 
in order to minimize neuronal or synaptic loss. Aiding in this is 
the use of a mnemonic table of disorders featuring as rapidly 
progressive dementias (RPDs) “VITAMINS” (V= vascular, 
I= infectious, T= toxic/metabolic/traumatic, A= autoimmune, 
M= metastatic/ neoplastic, I= iatrogenic/inborn disorders of 
metabolism, N= neurodegenerative, S= seizures/systemic) 
(Table 2).18-20
RPDs have a course, usually subacute, ranging between 
weeks, months up to two years. Conditions commencing as 
an acute confusional state, which evolve within hours or days, 
for instance acute infectious or metabolic encephalopathies, 
are excluded from this diagnosis.20 Prevailing etiologies differ 
analogous to the investigation’s point of view, like the refer-
ral centre or age group. According to the referral center, 
for example at the University of California, San Francisco, 
Memory and Aging Center, prion diseases (all types) are the 
most prominent rpd cause, while in a Greek tertiary referral 
centre secondary-potentially treatable nosologies are more of-
ten.19,21 In young patients, secondary dementias (vasculitis and 
autoimmune inflammatory brain diseases) are more common. 
Concerning prion disorders the variant Creutzfeldt- Jakob 
disease is typically observed in this age group.22
Strategies to best assess the vast number of entities, which 
manifest initially as rapidly progressive dementias are de-
picted in following algorithm (Table 3a, b). First it involves a 
meticulous history taking (time of onset, duration, associated 
features, co morbid conditions, evidence of systemic disease, 
exposure to toxic substances or blood products, family history, 
rashes, psychiatric symptoms, workplace, previous hospital 
admissions, etc.). This is succeeded by a thorough physical 
examination (neuropsychological testing, inspection for signs 
or symptoms pertaining to neurological, cardiovascular, pul-
monary, rheumatological, dermatological, gastroenterological 
disorders), laboratory (serum, CSF, urine) analysis, cerebral 
and whole body imaging studies, electroencephalographic 
evaluation and finally brain biopsy.19,22-24
Neuroimaging plays an important role in the differential 
diagnosis of dementia inducing conditions. Concerning cer-
ebral MRI characteristic is the “humming bird” or “penguin” 
sign noted in T1- weighted midsagittal images due to atrophy 
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Table 2. Differential Diagnosis of Rapidly Progressive Dementias with the aid of the mnemonic list “VITAMINS”.18-20
Vascular Multi-infarct vascular dementia, strategic infarct dementia, inflammatory cerebral amyloid 
angiopathy, primary CNS angiitis, cerebral venous sinus thrombosis, hyperviscosity syndromes
Infectious Viral encephalitis (including HSV), HIV dementia, progressive multifocal leukoencephalopathy 
(PML), subacute sclerosing panencephalitis, fungal and parasitic infections, treponema pallidum, 
mycobacterium tuberculosis, Whipple’s disease, Lyme disease
Toxic-Metabolic Vitamin B1, B12 and niacin deficiency, folate deficiency, uremia, electrolyte imbalances, hypothyro
idism,hyperparathyroidism, severe liver disorders, inherited metabolic disorders (leukodystrophies, 
Wilson’s disease, lysosomal and mitochondrial ), lead, aluminum, mercury, arsenic and bismuth 
toxicity 
autoimmune Paraneoplastic limbic encephalitis (anti-Hu, anti-CV2, anti-NMDA), Anti- VGKC and Anti-GAD 
encephalitis, Hashimoto encephalopathy, Systemic Lupus Erythematosus, Sjogren’s syndrome, 
primary or secondary CNS vasculitis, Coeliac and Behcet’s disease, neurosarcoidosis
Metastases/Neoplasm Metastatic tumors, primary CNS lymphoma, gliomatosis cerebri
Iatrogenic Lithium, valproic acid, anticancer drugs, benzodiazepines
Neurodegenerative CJD (sporadic, genetic, variant), Alzheimer’s disease, Lewy Body Dementia, behavioral variant 
frontotemporal dementia, corticobasal syndrome,progressive supranuclear palsy 
Systemic/seizures/other Hypertensive encephalopathy, eclampsia, chemotherapy, normal pressure hydrocephalus, non-
convulsive status epilepticus, psychiatric disorders
Abbreviations: CNS: central nervous system; HSV: herpes simplex virus; NMDA: N-methyl D-aspartate; GAD: glutamic acid decarboxylase; 
VGKC: voltage-gated potassium channel.
Table 3a. Diagnostic Algorithm for initially evaluating Rapidly Progressive Dementias according to Patterson RW 
et al modifications.19
basic panel of tests
blood tests cSF Imaging Urine/Other
Complete blood count, basic 
metabolic panel (including Ca, Mg 
and P), Liver and renal function 
tests, rheumatology screen (ESR, 
ANA, RF, CRP, C-ANCA and 
P-ANCA), thyroid function, B12, 
homocysteine, anti-thyroglobulin 
and anti-thyroperoxidase 
antibodies, HIV, Lyme, 
paraneoplastic and autoimmune 
antibodies, rapid plasma reagin
Cell count and differential, 
protein, glucose, IgG Index, 
Oligoclonal bands, VDRL, 
14-3-3 protein, neuron-
specific enolase, tau protein
Cerebral MRI [including 
FLAIR, DWI (diffusion 
weighted images) and 
ADC (apparent diffusion 
coefficient) sequences]  
with and without contrast
Urine Analysis and cultures, 
Collect 24-hour urine 
for heavy metal screen 
including: arsenic, lead, 
mercury, copper, aluminum 
and bismuth (relative to 
history of exposure).
Electroencephalogram
RAPIDLy EVOLVING DEMENTIAS
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of the midbrain tegmentum, considered a classical sign in 
progressive supranuclear palsy. Another is the “hot cross 
bun” sign caused by bilateral symmetric hyperintensity of the 
atrophic middle cerebellar peduncles observed in multiple 
system atrophy shown in T2- weighted MR images. In prion 
diseases, the “pulvinar” or “hockey stick” sign is indicative of 
variant CJD. It is formed by confluent hyperintensities within 
the dorsomedial thalamus and posterior thalamus (pulvinar). 
Diffusion weighted imaging (DWI) sequences and apparent 
diffusion coefficient (ADC) maps aid in the differentiation of 
CNS lymphoma, glioblastoma and metastatic lesions. While 
infectious aetiologies can be distinguished by combining 
serology tests and brain thalium-201 single-photon emission 
tomography (SPECT). Malignant and non-malignant cerebral 
lesions have also been accurately recognized by positron-
emission tomography (PET). The main neuroimaging findings 
in RPDs are demonstrated in Tables 4a and 4b.19,25-29
In the succeeding descriptions, the various types of 
Table 3b. Diagnostic Algorithm for initially evaluating Rapidly Progressive Dementias according to Patterson RW 
et al modifications.19
Tests to consider under various conditions
blood tests cSF Imaging Urine/ Other
Lyme disease, cancer screen, 
blood smear, coagulation 
profile, copper, ceruloplasmin, 
hypercoagulability tests, further 
rheumatologic examination 
(complement, dsDNA, anti-SM, 
anti-RNP, anticardiolipin, anti-
SCL 70, anti-Jo, anti-centromere 
antibodies)
Bacterial, fungal, acid-fast 
bacilli cultures and stains, 
flow cytometry, cytology, 
Whipple and viral PCRs, 
cryptococcal antigen, viral 
cultures
Cancer screen: CT of chest, 
abdomen, pelvis (with 
and without contrast), 
mammogram, body PET scan
Brain angiogram or MR 
angiography,
MR spectroscopy,
Carotid ultrasound,
Echocardiogram
24h urine screen for 
porphobilinogen, delta-
aminolevulinic acid, copper 
and heavy metals
Nerve conduction studies/
EMG
Brain biopsy
Table 4a. Neuroimaging findings in Rapidly Progressive Dementias caused by Neurodegenerative Disorders.19,25-29
Disease Neuroimaging investigation
Alzheimer’s disease Cerebral MRI: higher magnitude of atrophy in the occipital and parietal lobes
MR spectroscopy: decrease in N-acetylaspartate (NAA) and increase in myo-inositol and choline
Dementia with 
Lewy Bodies
Cerebral MRI: relative preservation of the medial temporal lobe (MTL), may be normal or non-specific 
atrophy
MR spectroscopy: preservation of NAA-to-creatine ratios
123 N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)-nortropane SPECT: reduced dopamine 
transporter levels
Frontotemporal 
Lobar Degeneration
Cerebral MRI: “knife edge” sign, which is due to focal atrophy within the anterior temporal lobe at the 
level of the temporal horn of the lateral ventricle
Progressive 
Supranuclear Palsy
Cerebral MRI: “humming bird or penguin” sign caused by atrophy of the midbrain, pons, thalamus, 
superior cerebellar peduncle, striatum
T2-weighted images very specific, but not always present, are hypointensities of the putamen and 
hyperintensities of the tegmentum
DWI sequences: possible demonstration of putaminal ADC value increase
Multiple System 
Atrophy
Cerebral MRI: “hot cross bun” sign in the pons
DWI demonstrates increased diffusivity and ADC within the affected middle cerebellar peduncles, with  
a matching decreased fractional anisotropy and putaminal ADC increases (not observed in Parkinson)
Corticobasal 
Syndrome
Cerebral MRI: Asymmetric parietal or frontal lobe atrophy
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RPDs are discussed, the relatively more often, somewhat 
more extensively. More rapidly progressive dementias have 
been observed with neurodegenereative diseases, prion dis-
eases, notably Creutzfeldt-Jakob disease (CJD), autoimmune 
and infectious diseases, toxic, vascular and metabolic disorders, 
neoplastic, paraneoplastic, systemic nosologies and seizures.
n e u r o d e g e n e r A t I v e  d I s o r d e r s
A large number of neurodegenerative diseases that usually 
progress gradually can also present as RPD. AD, as aforemen-
tioned, is the most common cause of dementia with a median 
survival rate of approximately 8-12 years. It can rarely present 
a rapid deterioration course, mimicking CJD, especially when 
combined with amyloid angiopathy. AD represents a major 
non-CJD RPD cause in some centres, while in others a much 
less common.6,20 Among other neurodegenerative diseases 
that can more likely portray a fulminant evolution are fron-
totemporal lobar degeneration (FLTD), dementia with Lewy 
bodies (DLB), corticobasal degeneration (CBD), progressive 
supranuclear palsy (PSP).24
F r o n t o t e m p o r A l  l o b A r 
d e g e n e r A t I o n
Frontotemporal lobar degeneration (FLTD) concerns 
pathologies that have a predilection to the frontal and/or 
temporal lobes early. The varying clinical and pathological 
presentations of this group of syndromes contributed to 
an extensive spectrum of referring terms. Briefly the term 
“frontotemporal lobar degeneration (FTLD)” is used when 
addressing the pathological entity and “frontotemporal de-
mentia” (FTD) in referral to the clinical one. Pick’s disease is 
the original term for frontotemporal degeneration. The term 
Pick’s disease is used at present for a specific pathology with 
Pick bodies, which are abnormal collections of the protein 
tau in the brain. These neuronal cytoplasmic inclusions stain 
slightly basophilic on routine hematoxylin-eosin staining. 
Though they are strongly argyrophilic after Bielschowsky or 
Bodian silver staining, pick bodies do not stain with Gallyas 
silver stain. Pick bodies by immunohistochemistry testing are 
revealed to be tau, RD3, p62, and ubiquitin immunoreactive 
and RD4, α-synuclein, and transactive response DNA-binding 
Table 4b. Indicative Neuroimaging findings in Rapidly Progressive Dementias caused by Vascular, Prion, Inflamma-
tory and other Nosologies.19,25-29
Disease Neuroimaging investigation
Vascular 
Diseases
Cerebral MRI: multiple regions of T2/FLAIR hyperintensities in vascular territories(Multi-Infarct 
Vascular Dementia), multiple grey or white matter T2 hyperintensities (primary CNS angiitis). In 
inflammatory CAA there are microbleeds on T2 with confluent hyperintensities (hypointensitities on T1)
Infectious Cerebral MRI: may be normal or shows non-specific atrophy in neurosyphilis, normal versus 
hyperintensities in MTL, midbrain and diencephalon in Whipple disease, normal in Lyme, cortical 
atrophy and nonspecific white matter changes in HIV Dementia, MTL hyperintensities on FLAIR 
sequences followed by asymmetric hemorrhagic necrosis in herpetic meningoencephalitis
Toxic-metabolic Cerebral MRI: T2 hyperintensities in medial thalamus and mammillary bodies in Wernicke 
syndrome, nondiagnostic in B12 deficiency, PallidalT1 hyperintensities with normal T2 in acquired 
hepatocerebral degeneration
Autoimmune Cerebral MRI: T2 hyperintensities in cerebral/ cerebellar cortex with meningeal contrast enhancement 
in NMDAR encephalopathy, MTL hyperintensities on FLAIR or normal in encephalopathy with 
VGKC antibodies, MTL hyperintensities on FLAIR and T2 or normal in Limbic encephalitis
Prion Disease Cerebral MRI: Flair and DWI sequences depict in sCJD the “cortical ribboning” sign (hypersignals 
delineating the cortex), hypersignals in the striatum and thalamus. In the vCJD the “pulvinar” sign is 
observed due to marked hyperintensity of the anterior putamen
Metastasis/
neoplasia
Cerebral MRI: focal hypo- or hyper T2 lesions with contrast enhancement in primary CNS lymphoma
Normal Pressure 
Hydrocephalus
Cerebral MRI: enlargement of ventricular system
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protein of 43 kDa (TDP-43) negative. Their cortical distribu-
tion typically involves neurons in the dentate gyrus, but also 
and other cortical areas, which include the cornu Ammonis 
of the hippocampus, presubiculum, cingulate gyrus, insula, 
inferior temporal lobe, and the inferior parietal lobule. Pick 
bodies are less prominent in the subcortical and brainstem 
area. Pick cells, pertaining to swollen chromatolytic neurons, 
are also typically found . Glial cell inclusions (often showing 
atypical 3R and 4R positivity) are less pronounced in Pick 
disease than in other tauopathies.20,30-32
Regarding the initial pathology, when it affects the fron-
tal lobes, the main changes are in personality and behaviour 
(Behavioral-variant FTD). Individuals with predominant 
temporal lobe involvement present with loss of language 
skills (Progressive Non-fluent Aphasia, Semantic Dementia). 
Frontotemporal lobar degeneration (FLTD) can be divided 
into various types according to histopathological findings or 
symptomatology.
The histopathology of FTLD in general is characterised 
by linear spongiosis in layers II and III of the cortex, with 
predominant neuronal loss and gliosis. The tau protein, 
transactive response DNA-binding protein of 43 kDa, and 
“fused in sarcoma” protein are proteins involved in patho-
logic processes that represent the basis for frontotemporal 
lobar degeneration classification. From the histopathological 
point of view the FTLD can be classified into 4 groups based 
on the presence of aggregates or deposits in neurons or glial 
cells: tauopathies, ubiquitinopathies, neuronal intermediate 
filament inclusion disease, and those with no data specifically 
pertaining to any of the above types. There are types of FTLD 
with tau inclusions (FLTD-tau) and others containing TAR 
DNA-binding protein 43 (FTLD-TDP). On the basis of the 
number of microtubule-binding repeats in the tau protein 
(a consequence of differential mRNA splicing), FTLD-tau 
pathologies are further classified into 3R, 4R, or combined 
3R/4R subtypes. Overlapping FTLD–motor neuron disease 
and FTLD–parkinsonism syndromes are relatively frequent. 
These nosologies predispose to a fast progression of the 
disorder.20,30-32 
Clinically, FTD is divided into the following categories: 
behavioral variant of FTD (bvFTD), concerning executive 
function and behaviour (as bvFTD progresses disinhibition 
develops, and there is a remarkable loss of restraint in personal 
relationships and social life); primary progressive aphasia 
(PPA), a progressive language disorder, and its three sub-
types: a) progressive non-fluent aphasia (PNFA), b) semantic 
dementia (SD), c) logopenic progressive aphasia (LPA). In 
PNFA the ability to generate words is lost, and speech becomes 
halting and ungrammatical. The ability to read and write also 
may be impaired. SD is marked by easy speech, but the words 
conveyed have less and less meaning. There is a tendency 
to use broader general terms. Also language comprehen-
sion declines. The third PPA subtype, logopenic progressive 
aphasia (LPA), represents an atypical language presentation 
of AD-neuropathology. 
In FTD the clinical presentation varies, depending on 
whether the frontal or temporal lobe is affected first. It is 
also noted that a considerable phenotypical overlap exists 
between FTD and amyotrophic lateral sclerosis (ALS). 30% 
of FTD patients develop clinical symptoms of motor neuron 
dysfunction. FTD represents a common cause of RPD, with an 
incidence and prevalence in some studies similar to that of AD 
and in which it is considered the second most often. SPECT 
or FDG-PET scans have aided in distinguishing between FTD 
and AD. There exists a pattern of hypometabolism in frontal 
association cortex, anterior temporal cortex, and anterior 
cingulate cortex in FTD as to a pattern of hypometabolism 
in posterior cingulate and posterior association cortex in 
AD. Cerebral MRI in CBS reveals asymmetric atrophy of the 
perirolandic cortex and basal ganglia, whilst PSPS has been 
associated with atrophy of the midbrain, superior cerebellar 
peduncle and frontal white matter, with lesser involvement of 
the frontal cortex.20,30-32
c o r t I c o b A s A l  d e g e n e r A t I o n
Corticobasal degeneration (CBD) is considered a 4R 
tauopathy, portrayed as an atrophy of the corpus callosum, 
but not so prominent in subcortical regions. Characteristic 
asymmetric focal atrophy of the frontal and parietal lobes is 
depicted, with a relative sparing of the brainstem and cerebel-
lum. There is some loss of pigmented neurons in the substantia 
nigra. Pick-like inclusions, which are spherical corticobasal 
bodies may be found in neurons, mostly in the frontal and 
parietal cortex. They are tau-4R immunoreactive and can be 
stained with Gallyas, Some distinctive features of CBD are 
the numerous Gallyas- and tau-immunoreactive threads in 
the neuropil of affected gray matter structures and adjacent 
white matter as well as the swollen chromatolytic neurons 
(sometimes called “ballooned neurons”) and the presence 
of astrocytic lesions called “astrocytic plaques” with typical 
peripheral Gallyas- and tau-4R–immunoreactive inclusions 
in astrocytes.31
Progressive loss of the ability to control movement is 
noted, typically beginning around age 60. The most promi-
nent symptom is apraxia (inability to use the hands or arms 
to perform a movement despite normal strength). Symptoms 
may appear first on one side of the body, but eventually both 
sides are affected. Sometimes language problems or trouble 
orienting objects in space are the first presenting symptoms 
with the movement disorders developing later.31
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p r o g r e s s I v e  s u p r A n u c l e A r  p A l s y 
As noted in other tau-related pathologies, progressive 
supranuclear palsy (PSP), also called Steele-Richardson-
Olszewski syndrome, may progress as RPD. PSP is usually 
sporadic, even though autosomal dominant cases have been 
described. High PSP risk has been associated with the H1 
haplotype of the tau gene (MAPT). Furthermore some of the 
MAPT mutations linked to chromosome 17, which have been 
known to be associated with familial frontotemporal dementia 
with parkinsonism (FTDP-17 and/or FTLD-tau) cause pheno-
types resembling PSP. The motor symptoms associated with 
this pathology can easily be misdiagnosed as CJD. Cardinal 
symptoms are inability to coordinate the eyes in order to look 
up or down. Some patients experience this visual deficit as blur-
ring. Loss of balance and gait instability resulting in increased 
likelihood of falls, slowness and stiffness of movements, simi-
lar to that seen in Parkinson disease, dysphagia, dysarthria , 
immobile, “masked face” and forced laughing or crying are 
also observed. The most characteristic gross finding in PSP 
is atrophy of the superior cerebellar peduncle due to loss of 
neurons in the dentate nucleus. Also the subthalamic nucleus 
is often atrophied and the substantia nigra is depigmented. 
The rest of the gross cerebral examination is unremarkable 
or may demonstrate mild cortical and midbrain atrophy with 
mildly dilated ventricles. Concerning the pathology of the 
lesions there are typical findings of “pretangles”, which are 
diffuse granular cytoplasmic inclusions immunoreactive for 
tau and also cytoplasmic, globose 4R-tau–immunoreactive 
inclusions. Tufted astrocytes, containing argyrophilic and 
tau-immunoreactive inclusions located toward the center of 
astrocytes, and oligodendroglial coiled bodies, which consti-
tute tau-immunoreactive, rounded, cytoplasmic inclusions are 
found in glial lesions.20,31,33,34
A r g y r o p h I l I c  g r A I n  d I s e A s e 
Argyrophilic Grain Disease (AGD) is usually a sporadic 
entity, which may manifest with dementia and behavioral 
abnormalities such as emotional and mood imbalance. Tau 
pathology (silver stained or argyrophylic grains) at hippocam-
pal formation and amygdala regions, as well as involvement of 
anterior medial temporal lobe regions with further extension 
to limbic cortices, certain subcortical nuclei, and brainstem 
tegmentum, are thought to be responsible for AGD symp-
tomatology. These characteristic argyrophilic grains can be 
demonstrated with Gallyas silver stain, Bodian and Biels-
chowsky stains, and by a positive immunohistochemical reac-
tion for tau protein, its 4R isoform, and p62 and are scattered 
throughout the neuropil in both cortical and subcortical areas. 
Most susceptible as aformentioned, are limbic structures, 
mainly transentorhinal and entorhinal cortex. Non-specific 
pathologies can also be found in AGD,such as Gallyas- and 
tau-immunoreactive oligodendroglial coiled bodies (found 
also and in other taupathies) and ballooned neurons (mainly 
in the limbic lobe). MRI findings are usually unremarkable, 
although mild medial temporal lobe atrophy may be seen. 
AGD is considered a distinct neuropathologic entity, which 
can present with Alzheimer disease–like pathologic changes 
(AT8-immunoreactive neuronal cytoplasmic inclusions) 
and may frequently coexist with another neurodegenerative 
disease.31,35,36 
d e m e n t I A  w I t h  l e w y  b o d I e s
Dementia with Lewy bodies (DLB) the second most 
common type of neurodegenerative dementia after AD, 
with estimated prevalences of 0.7% in individuals aged 65 
and older. In addition to dementia, central features of DLB 
include fluctuations in attention, alertness or cognition, visual 
hallucinations, and parkinsonism. DLB patients also exhibit 
severe sensitivity to neuroleptic medications and autonomic 
dysfunction. Lewy bodies, the pathologic hallmark of DLB, 
consist of eosinophilic cytoplasmatic inclusion bodies contain-
ing ubiquitin, α-synuclein neurofilament and other proteins 
distributed throughout the cortical and subcortical structures 
of the central nervous system (CNS) as well as in peripheral, 
and autonomic nervous systems.22
p r I o n  d I s e A s e
Prion diseases (PrDs) are a group of transmissible 
neurodegenerative disorders belonging to the category of 
transmissible spongioform encephalopathies. They are caused 
by infectious proteins called prions. PrDs occur in humans 
and many other species (scrapie in sheep and goats, bovine 
spongiform encephalopathy in cattle). There exists a variety 
of subgroups of human PrDs, which can be classified into 
three categories: sporadic (85–90%), genetic (10–15%), and 
acquired (1–3%).The sporadic form is represented by sporadic 
Creutzfeldt- Jakob (sCJD). The genetic types are subdivided 
into genetic CJD (gCJD), Gerstmann-Sträussler-Scheinker 
disease (GSS), and familial fatal insomnia (FFI). The acquired 
forms include variant CJD (vCJD) disease, Kuru and iatro-
genic CJD (iCJD). The most common human phenotype of 
human PrDs is Creutzfeldt- Jakob disease (CJD). Concerning 
the pathophysiology of PrDs it is believed to be due to the 
propagation of abnormally conformed infectious proteins, 
the prions. This abnormal protein is named PrPSc, which is 
a mostly β-pleated sheet structure. In PrPSc the superscript 
Sc comes from scrapie and it is considered a conformational 
isoform of the normal cellular prion-related, α-helical struc-
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tured, protein referred to as PrPC. The normal PrPC is a 
membrane-bound protein that is predominantly expressed in 
nervous tissue. It is thought to take part in neuronal devel-
opment and function although its physiologic function is not 
entirely known. It has been shown that PrPC participates in 
immunological homoeostasis by regulating T cell receptor-
mediated T cell activation. The pathogenic PrPSc acts as a 
template to convert PrPC into PrPSc by misfolding it as PrPC 
comes into contact with the abnormal protein . It is through 
this mechanism that prion infectivity takes place. In turn this 
new PrPSc becomes a new template for conversion of existing 
PrPC, initiating a autocatalytic cascade reaction, that leads 
to neuronal destruction. Prions do not need nucleic acids or 
other co- factors to transmit disease. PrPSc is also character-
ized by resistance to nucleic acid destroying procedures and 
protease K. Diagnosis is definitely made neuropathologically. 
Tests assisting in the diagnosis are the electroencephalogram 
(EEG), cerebrospinal fluid (CSF) examination and cerebral 
MRI. The EEG findings consist of periodic sharp wave 
complexes (PSWCs), observed in approximately two-thirds 
of patients, but vary depending on disease phase. From the 
CSF examination, the presence of the 14-3-3 protein points 
to CJD, but this protein is a nonspecific index of neuronal 
injury, since it has been also detected in CSF of patients 
with non-CJD nosologies (metabolic encephalopathies, 
cerebrovascular disease, CNS infections, neurodegenerative 
dementias). Signal abnormalities in the basal ganglia and/
or cortical ribbon on diffusion weighted imaging (DWI) and 
fluid attenuated inversion recovery (FLAIR) sequences as 
featured in the brain MRI aid in the diagnosis. This has been 
added to the differential criteria of probable CJD. Clinically, 
CJD patients demonstrate rapidly progressing mental decline 
and within a few weeks to several months there is onset of 
dementia, ataxia, and visual disturbances, while myoclonus 
occurs with disease progression.37-43 
s p o r A d I c  c r e u t z F e l d t -  J A K o b
The incidence of sCJD is found to be about 1 to 1.5 per 
million per year. Officially reported national incidence rates 
vary from 0.48 to 2.23/million population/year. The age of 
onset has a large range that of 12 to 98 years with a peak age 
of about 68. In individuals younger than 30 years Creutzfeldt- 
Jakob disease is rare, and mostly is either acquired or genetic. 
In sCJD subgroup there is no gender predilection, although 
there seems to be a female preponderance. Sporadic PrD is 
probably the result of spontaneous folding of PrPC into PrPSc 
or a somatic mutation in the prion protein gene (PRNP gene). 
The PRNP gene is located on the short (p) arm of chromo-
some 20. There are currently more than 30 known mutations 
in this gene.
g e n e t I c  p r I o n  d I s o r d e r s
Genetic prion disorders include various subtypes, such 
as genetic Creutzfeldt-Jakob (gCJD), Gerstmann-Straussler-
Scheinker disease and fatal familial insomnia (FFI). The 
genetic Creutzfeldt-Jakob (gCJD) has an autosomal dominant 
pattern of inheritance with a high age-dependant penetrance. 
Among mutation carriers of Libyan Jewish heritage the 
penetrance was calculated to be around 1% at age 40, only 
to reach close to 100% after the ninth decade of life. PRNP 
polymorphisms can also influence a patient’s susceptibility to 
develop disease. Sometimes this group of disorders is called 
familial. Genetic CJD is associated with younger ages and 
a longer survival. Gerstmann-Straussler-Scheinker disease, 
usually appearing in the fourth to six decade, has a subacute 
progressive ataxic symptomatology. Parkinsonian features, 
cognitive decline, pyramidal signs, areflexia and dysesthesia 
also set in later. Fatal familial insomnia, with an onset at the 
fifth and sixth decade of life, manifests as severe, progressive 
insomnia, accompanied by dysautonomia, cognitive decline 
and motor signs.20,40
A c q u I r e d  h u m A n  p r I o n  d I s o r d e r s
Under the acquired human prion disease category are 
three main types of disorders; Kuru, variant Creutzfeldt-Jakob 
and iatrogenic CJD. Kuru and most cases of vJCD are orally 
acquired forms of PrD. The prions are uptaken through the 
intestinal epithelium and then accumulate in lymphoid tissue 
before being transported via sympathetic and parasympathetic 
nerves to the central nervous system. Variant CJD is different 
from sCJD. vCJD occurs in the younger age groups (mean age 
27 years) and has a longer course with psychiatric symptoms 
being the first presentation of the disorder. It has been associ-
ated with bovine spongiform encephalopathy, which is believed 
to be the only directly transmissible animal encephalopathy to 
humans. Characteristic cerebral MRI finding of vCJD is the 
“pulvinar sign”, which is due to a brighter posterior thalamus 
than the basal ganglia on T2-weighted sequences. Iatrogenic 
CJD has been caused by injection of growth hormone and 
gonadotrophin extracted from contaminated cadaveric pi-
tuitaries, dural grafts, corneal transplants, blood products or 
surgical instruments.40,42,43
A u t o I m m u n e  d e m e n t I A s
Autoimmune RPDs encompass an enormous spectrum of 
pathologies, which display potentials for therapeutic interven-
tion, in contrast to neurodegenerative diseases that have very 
limited treatment options. By promptly using immunomodu-
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latory agents or treatment for the underlying etiology, there 
exists a possibility of responsiveness and remission. The im-
munologically mediated dementias can be divided into two 
main categories depending upon the finding or not of specific 
antigens and antibodies. In the first category are paraneoplas-
tic syndromes (limbic encephalitis) and nonparaneoplastic 
syndromes, such as anti–voltage-gated potassium channel 
encephalopathy (anti–VGKC-E), anti–glutamic acid decar-
boxylase (anti-GAD) syndrome, Hashimoto’s encephalopathy 
(HE), systemic lupus erythematosus (SLE), and Sjögren’s 
encephalopathy. The second autoimmune dementia group 
includes diseases, which are not associated with known specific 
antigens or antibodies (sarcoidosis, Behçet’s disease, primary 
angiitis of the central nervous system).18,19,22,44
In paraneoplastic syndromes the immune-mediated injury 
to the cerebral system is caused by shared antigens, which are 
expressed both in the nervous system (NS) and on tumor cells. 
Most of these syndromes do not respond to immunomodula-
tory treatments and persist unless the underlying neoplasm is 
treated. Patients with limbic encephalitis associated with anti-
Hu antibodies usually have small cell lung carcinoma, while 
those with anti-CV2 antibodies (anti–collapsin response medi-
ated protein 5) exhibit thymoma and with anti-Ma2 antibodies 
testis germ-cell tumors, breast and non–small cell lung cancer. 
Frequently, in younger women presenting with anti–N-methyl-
d-aspartate receptor (anti-NMDAR) antibody–associated 
encephalopathy ovarian teratoma is the underlying tumor. 
Anti-Ri (anti–neuronal nuclear antibody-2 (anti–ANNA-2) 
antibodies are related to breast cancer, ovarian malignancy, 
and small cell lung cancer.18,24,44
Concerning non-paraneoplastic syndromes, the anti–
voltage-gated potassium channel encephalopathy can be 
easily mistaken for CJD because of overlapping symptoms, 
biochemical testing results and neuroradiological findings. It 
is responsive to immunotherapy, so early diagnosis is impera-
tive. Hashimoto’s encephalopathy, which responds to high-
dose corticosteroids, is correlated with increased circulating 
antithyroperoxidase or antithyroglobulin antibodies. It has a 
prevalence estimated at 2.1 in 100,000 subjects and female 
preponderance.44,45
v A s c u l A r  r p d s
Vascular disorders, such as bilateral thalamic infarcts, cer-
ebral amyloid angiopathy, dural arteriovenous fistulas, cerebral 
venous sinus thrombosis and hypertensive encephalopathy, 
may present as a rapidly evolving dementia. More rare and 
usually fatal causes of vascular rpd are cerebroretinal micro-
angiopathy and subacute diencephalic angioencephalopathy. 
The latter being considered a deleterious type of posterior 
reversible encephalopathy.24
p o t e n t I A l l y  r e v e r s I b l e  r p d s
Reversible rapidly progressive dementia can be caused by 
a number of conditions such as bismuth, lithium, mercury and 
arsenic toxicity, alcoholic dementia, vitamin B1, B12 deficiency, 
niacin and folate deficiency, uremia, electrolyte abnormalities, 
normal pressure hydrocephalus, hyperviscosity syndromes. 
Infectious diseases may have a subacute course and appear 
as rpds. Among these are syphilis, fungal/viral meningoen-
cephalitis (e.g., aspergillosis, herpes encephalitis), Whipple’s 
disease (a Tropheryma whipplei infection), parasitic infections 
and Lyme disease.20,22
c o n c l u s I o n
Rapidly progressive dementias are not only a subtype of 
Alzheimer’s disease, but a diverse compilation of heterogenous 
entities, which warrant meticulous investigation, since some 
disorders can be treated, showing full remission, if therapeutic 
intervention is commenced immediately. This review touched 
only the “tip of the iceberg” of rapidly progressive dementias in 
an effort to increase awareness of these challenging conditions.
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